Robert E. Gagnon - 18 Mar 2026 Form 3 Insider Report for PURPLE BIOTECH LTD. (PPBT)

Reporting relationship: Director
Issuer ticker: PPBT
Reported as of: 18 Mar 2026
Net transaction value: $0
SEC form: 3
Accepted by SEC: 18 Mar 2026, 18:06:33 UTC
Prior SEC filing: 26 Jan 2026
Next SEC filing: 27 Apr 2026
Source filing: View source filing
Reporting owner signature: /s/ Robert Gagnon

Key filing fact

Robert E. Gagnon filed Form 3 for PURPLE BIOTECH LTD. (PPBT) on 18 Mar 2026.

Key facts

This page summarizes Robert E. Gagnon's Form 3 filing for PURPLE BIOTECH LTD. (PPBT).
0 reported transactions and 3 derivative rows are listed below.
Accepted by SEC: 18 Mar 2026, 18:06.

Change

Previous filing in this sequence was filed on 26 Jan 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Official SEC source

Ownership activity is grounded in SEC Form 3 disclosures.

View source filing

Reporting Owners (1)

CIK 0001504983 Primary reporting owner

Gagnon Robert E.

Relationship: Director
Address: 14 WHITRIDGE RD, NATICK
Signature: /s/ Robert Gagnon
Signature date: 18 Mar 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

PPBT holding

Ordinary Shares

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 3,062,500
Date: 18 Mar 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

PPBT holding Derivative

Stock Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 18 Mar 2026
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 112,500
Exercise price
Footnotes: F2

PPBT holding Derivative

Stock Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 18 Mar 2026
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 300,000
Exercise price
Footnotes: F3

PPBT holding Derivative

Stock Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 18 Mar 2026
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 2,650,000
Exercise price
Footnotes: F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

Includes 2,454,167 unvested restricted stock units ("RSUs"), each with respect to one ordinary share, no par value, per share ("Ordinary Shares"), of Purple Biotech Ltd. (the "Issuer"). The RSUs are subject to time-based vesting conditions and are settled in Ordinary Shares. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents 2,000 Ordinary Shares

Footnote F2

Represents stock option to purchase 112,500 Ordinary Shares (equivalent to 56 ADSs), issued to the reporting person pursuant to the Issuer's 2016 Equity-Based Incentive Plan. The shares underlying this stock option are fully vested and exercisable. The exercise price of this stock option is $0.146765625 per Ordinary Share and the option expires on December 29, 2026.

Footnote F3

Represents stock option to purchase 300,000 Ordinary Shares (equivalent to 150 ADSs), issued to the reporting person pursuant to the Issuer's 2016 Equity-Based Incentive Plan. Options to purchase 274,997 Ordinary Shares are vested and exercisable, with the remaining options to purchase 25,003 Ordinary Shares vesting in equal quarterly installments until April 24,2026.The exercise price of this stock option is $0.059375 per Ordinary Share and the option expires on April 24, 2028.

Footnote F4

Represents stock option to purchase 2,650,000 Ordinary Shares (equivalent to 1,325 ADSs), issued to the reporting person pursuant to the Issuer's 2016 Equity-Based Incentive Plan. Options to purchase 220,833 Ordinary Shares are vested and exercisable, with the remaining options to purchase 2,429,167 Ordinary Shares vesting in equal quarterly installments until October 21, 2029.The exercise price of this stock option is $0.00309375 per Ordinary Share and the option expires on October 21, 2030.